Key takeaways
- +23.5m vs −13.2m 6MWT change for avalglucosidase alfa vs alglucosidase alfa (COMET trial) — the core evidence behind NICE's TA821 recommendation
- ~180 UK Pompe patients currently on alglucosidase alfa via NHS clinical commissioning policy — the documented population any switch programme must convert
- ≥12 months Expected minimum duration of documented inadequate response (FVC decline ≥5% or 6MWT decline ≥10%) the UK Pompe Consortium is defining as the NHS switch-eligibility gate
NHS-commissioned alglucosidase alfa covers ~180 UK Pompe patients; avalglucosidase alfa's NICE recommendation (TA821) has already opened the next switch-programme access event.
An estimated 200 UK patients, infantile- and late-onset combined, receive enzyme replacement therapy for Pompe disease, commissioned by NHS England Highly Specialised Services via clinical commissioning policy (alglucosidase alfa predates NICE's routine technology appraisal of ultra-orphan ERTs and has never been formally appraised by NICE) at 6-8 specialist metabolic disease centres, including Guy's and St Thomas', Manchester, Birmingham, and Queen Elizabeth Edinburgh. Infantile-onset patients begin alglucosidase alfa (Lumizyme/Myozyme, Sanofi) directly from newborn-screening confirmation, while late-onset patients require documented FVC decline or functional impairment before ERT initiation is authorised. Alglucosidase alfa remains the dominant, NHS-commissioned ERT: roughly 180 of the estimated 200 UK Pompe patients are on it today.
Nexviazyme (avalglucosidase alfa, Sanofi) is NICE-recommended as the first switch candidate (TA821, published 24 August 2022, with a commercial arrangement already in place): the COMET trial showed a 23.5-metre 6-minute-walk-test improvement against a 13.2-metre decline for alglucosidase alfa, alongside better forced vital capacity preservation. With the appraisal and commercial arrangement already settled, the constraint on switching late-onset patients is now the pace of NHS conversion, not a pending cost-effectiveness decision. Pombiliti + Opfolda (cipaglucosidase + miglustat, Amicus), which showed a 20.8-metre 6MWT improvement in switch patients in the PROPEL trial, sits further back in the NICE appraisal queue and is currently accessible only via named-patient exceptional commissioning. The UK Pompe Consortium is establishing consensus on the inadequate-response criteria (expected to require a documented FVC decline of at least 5% or 6MWT decline of at least 10% over a minimum of 12 months) that will gate NHS switch eligibility for both next-generation agents.
Approved Pompe Disease ERT agents — UK, 2026
| Drug (Brand / INN) | Mechanism | Company | UK Approval / NICE Status | Key Trial Result | NHS Commissioning Status |
|---|---|---|---|---|---|
| Lumizyme / Myozyme (alglucosidase alfa) | First-gen ERT IV | Sanofi | MHRA approved; NHS-commissioned via clinical policy (no NICE TA/HST) | LOTS trial; NHS HSS clinical policy covers infantile- and late-onset Pompe | NHS HSS commissioned; dominant ERT, ~180 of ~200 UK Pompe patients |
| Nexviazyme (avalglucosidase alfa) | Next-gen ERT IV | Sanofi | MHRA approved 2022; NICE TA821 recommended with commercial arrangement (24 Aug 2022) | COMET trial; +23.5m 6MWT vs −13.2m for alglucosidase alfa | NHS commissioning live following TA821 recommendation (2022) |
| Pombiliti + Opfolda (cipaglucosidase + miglustat) | Next-gen ERT + chaperone | Amicus | MHRA approved 2023; NICE appraisal not yet initiated | PROPEL trial; 20.8m 6MWT improvement in switch patients | Pre-NICE; named-patient access via exceptional commissioning |
Sources: MHRA public assessment reports; NHS England Highly Specialised Metabolic Diseases clinical commissioning policy (alglucosidase alfa); NICE TA821 (avalglucosidase alfa, 24 August 2022); COMET trial, NEJM 2022; PROPEL trial; NHS England Highly Specialised Metabolic Diseases specification 2022; UK Pompe Consortium clinical consensus meeting 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- With avalglucosidase alfa already NICE-recommended (TA821) and a commercial arrangement in place, how quickly will NHS metabolic centres convert eligible late-onset patients off alglucosidase alfa? • TA821 commercial arrangement terms • NHS conversion timelines from comparable ERT switch programmes • centre-level capacity constraints on re-consenting and re-titrating patients
- What inadequate-response criteria will the UK Pompe Consortium finalise for switching NHS patients from alglucosidase alfa to avalglucosidase alfa or Pombiliti + Opfolda? • Draft FVC/6MWT threshold consensus • anti-drug-antibody confounding rules • centre-level practice across the 6-8 NHS HSS metabolic centres
- Where does Pombiliti + Opfolda sit in the NICE appraisal queue now that avalglucosidase alfa has already secured a positive TA821 recommendation, and what NHS commissioning position remains once the first switch programme is underway? • NICE appraisal sequencing behind TA821 • Amicus's named-patient access pathway • competitive positioning once NHS conversion onto avalglucosidase alfa is underway
What's inside
-
1 · Market Map & NHS HSS Commissioning 4 pp
- Why NHS England Highly Specialised Services commission Pompe disease care via clinical policy at 6-8 specialist metabolic centres for an estimated 200 UK patients
- How infantile-onset patients begin alglucosidase alfa directly from newborn-screening confirmation while late-onset patients require documented FVC decline first
-
2 · Competitive Drug Profiles (3 agents) 6 pp
- Full profiles of alglucosidase alfa (Lumizyme/Myozyme), avalglucosidase alfa (Nexviazyme, NICE TA821) and cipaglucosidase + miglustat (Pombiliti + Opfolda)
- Mechanism, sponsor, trial evidence and NHS commissioning status for all three agents, from Sanofi's first-generation ERT through Amicus's combination therapy
-
3 · Switch Criteria & Inadequate-Response Analysis 4 pp
- How the UK Pompe Consortium is defining inadequate-response criteria, expected to require FVC decline of at least 5% or 6MWT decline of at least 10% over 12 months
- Why these switch-eligibility thresholds, not cost-effectiveness alone, will gate NHS conversion from alglucosidase alfa to next-generation agents
-
4 · NICE Appraisal Landscape (Clinical Policy ERT, TA821, Pombiliti Queue) 5 pp
- Why alglucosidase alfa was never formally appraised by NICE, having predated routine ultra-orphan ERT technology appraisals, unlike avalglucosidase alfa's TA821
- How Pombiliti + Opfolda sits further back in the NICE appraisal queue, currently accessible only via named-patient exceptional commissioning
-
5 · NHS Metabolic Centre Network & KOLs 3 pp
- How the 6-8 NHS metabolic disease centres, including Guy's and St Thomas', Manchester, Birmingham and Queen Elizabeth Edinburgh, concentrate Pompe prescribing
- Why roughly 180 of the estimated 200 UK Pompe patients remaining on alglucosidase alfa defines the population any switch programme must convert
-
6 · PAS Pricing & Cost-Effectiveness Modelling 4 pp
- Why avalglucosidase alfa's TA821 recommendation, backed by a 23.5-metre 6MWT improvement versus a 13.2-metre decline in COMET, already carries a commercial arrangement
- How Pombiliti + Opfolda's 20.8-metre 6MWT improvement in the PROPEL trial positions it as a third competitor once it clears NICE appraisal
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom brief delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this brief
AXLRx delivers Pompe Disease competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams targeting the UK market. Custom brief in 72 hours.
- 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
- 3. DeliveryResearch-verified brief in 72 hours with optional analyst readout.
How AXLRx builds this brief
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx brief is built from primary regulatory sources (MHRA, NICE, NHS England), peer-reviewed literature, and live NHS commissioning documentation — not secondary summaries. Findings are independently verified before inclusion.
Pompe Disease UK CI sources: MHRA public assessment reports, NHS England Highly Specialised Metabolic Diseases clinical commissioning policy (alglucosidase alfa), NICE TA821 (avalglucosidase alfa, 24 August 2022), COMET trial (NEJM 2022), PROPEL trial, NHS England Highly Specialised Metabolic Diseases specification (2022), and UK Pompe Consortium clinical consensus documentation (2023).
- Drug approval dates verified against MHRA public assessment reports and NICE technology appraisal documents
- Clinical trial results (COMET, PROPEL, LOTS) verified against published primary sources
- NICE appraisal status verified against the current NICE appraisal tracker (nice.org.uk)
- NHS commissioning status verified against NHS England Highly Specialised Services specifications
Frequently asked questions
Deliverables What formats are included with every brief?
Every commissioned brief includes three deliverables: a 20–30 page PDF analyst brief with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.
Sources What sources does AXLRx use, and how are findings verified?
AXLRx builds from primary sources only: MHRA public assessment reports, NHS England highly specialised metabolic-disease commissioning policy and service specification, the relevant NICE technology appraisal, and the primary enzyme-replacement trial publications. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered brief.
Customisation Can I tailor the brief to my specific question, geography, or comparator set?
Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard brief. Commission via the intake form to start.